# Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

> **NCT03622541** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 46 (actual)

## Conditions studied

- FLT3-ITD Mutation
- AML

## Interventions

- **DRUG:** Sorafenib 200mg

## Key facts

- **NCT ID:** NCT03622541
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-15
- **Primary completion:** 2019-12-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622541, "Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03622541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*